Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cytochalasin H ((16-Benzyl-5,12-dihydroxy-5,7,14-trimethyl-13-methylidene-18-oxo-17-azatricyclo[9.7.0.01,15]octadeca-3,9-dien-2-yl) acetate) 是肌动蛋白掺入细丝的有效抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,610 | 现货 | ||
5 mg | ¥ 3,970 | 现货 | ||
10 mg | ¥ 5,790 | 现货 | ||
25 mg | ¥ 8,860 | 现货 | ||
50 mg | ¥ 11,900 | 现货 | ||
100 mg | ¥ 15,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 6,860 | 现货 |
产品描述 | Cytochalasin H ((16-Benzyl-5,12-dihydroxy-5,7,14-trimethyl-13-methylidene-18-oxo-17-azatricyclo[9.7.0.01,15]octadeca-3,9-dien-2-yl) acetate) is a potent inhibitor of actin incorporation into filaments. |
体外活性 | Cytochalasin H significantly inhibited angiogenesis in vitro and in vivo, and suppressed the hemoglobin content and HIF-1α and VEGF protein expression in xenografted NSCLC tissues of nude mice. Meanwhile, Cytochalasin H inhibited the secretion of VEGF protein and the expression of HIF-1α protein in A549 and H460 cells. Moreover, Cytochalasin H had a significant inhibitory effect on VEGF mRNA expression but had no effect on HIF-1α mRNA expression, and Cytochalasin H inhibited HIF-1α protein expression by promoting the degradation of HIF-1α protein in A549 and H460 cells. Additionally, CyH dramatically inhibited AKT, P70S6K, and ERK1/2 activation in A549 and H460 cells. |
别名 | (16-Benzyl-5,12-dihydroxy-5,7,14-trimethyl-13-methylidene-18-oxo-17-azatricyclo[9.7.0.01,15]octadeca-3,9-dien-2-yl) acetate, 细胞松驰素 H |
分子量 | 493.63 |
分子式 | C30H39NO5 |
CAS No. | 53760-19-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (101.29 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0258 mL | 10.129 mL | 20.2581 mL | 50.6452 mL |
5 mM | 0.4052 mL | 2.0258 mL | 4.0516 mL | 10.129 mL | |
10 mM | 0.2026 mL | 1.0129 mL | 2.0258 mL | 5.0645 mL | |
20 mM | 0.1013 mL | 0.5065 mL | 1.0129 mL | 2.5323 mL | |
50 mM | 0.0405 mL | 0.2026 mL | 0.4052 mL | 1.0129 mL | |
100 mM | 0.0203 mL | 0.1013 mL | 0.2026 mL | 0.5065 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Cytochalasin H 53760-19-3 Proteases/Proteasome MMP (16-Benzyl-5,12-dihydroxy-5,7,14-trimethyl-13-methylidene-18-oxo-17-azatricyclo[9.7.0.01,15]octadeca-3,9-dien-2-yl) acetate 细胞松驰素 H Inhibitor inhibitor inhibit